Coronavirus Briefing: A promising new vaccine

Experts are particularly curious about an RNA vaccine from a small German company called CureVac.

An informed guide to the pandemic, with the latest developments and expert advice about prevention and treatment.

(Was this email forwarded to you? Sign up here.)

The New York Times

Second wave vaccines

As terrifying outbreaks erupt around the world, governments are scrambling to tap into the global supply of vaccines. But with so few doses to go around, many countries, particularly those in the developing world, are looking toward an upcoming "second wave" of vaccines.

Several have potential: Novavax, based in Maryland, is expected to apply for U.S. authorization in the next few weeks. The Indian pharmaceutical company Biological E is testing a vaccine that was developed by researchers in Texas. And researchers in Brazil, Mexico, Thailand and Vietnam are starting trials for a Covid-19 shot that can be mass-produced in chicken eggs.

My colleague Carl Zimmer, who covers science for The Times, told me that experts are particularly curious about an RNA vaccine from a small German company called CureVac, which entered the RNA vaccine business before BioNTech and Moderna. CureVac could announce results from its late-stage vaccine trial as early as next week.

"Moderna and Pfizer-Biotech demonstrated that RNA vaccines can work incredibly well," Carl said. "They are about as good as a vaccine can be, in terms of protection, as far as we can tell right now. So it's possible that CureVac might also be really effective, too."

To be sure, the trial results are not in yet. "And CureVac does have some differences in how it creates its RNA," Carl said. "So we'll have to see if those differences translate into how well the vaccine performs."

But if it works, CureVac's shot would have an important advantage over the other RNA vaccines: While Pfizer and Moderna must be kept in a deep freezer, CureVac's vaccine remains stable in a refrigerator and can sit for 24 hours at room temperature before it is used, properties that may make it easier to deliver to hard-hit places around the world.

If successful, Carl said CureVac could be ready to deliver 1 billion doses by next year. But there's still a huge demand for the raw materials needed to create RNA vaccines, so even if the results are good, Carl said, "it will definitely still be a scramble."

Biden backs waiving vaccine patents

As the gap in vaccinations between the world's richest and poorest countries widens, it's creating a stark split screen: People are busy lining up summer vacations in the U.S. and Europe while residents gasp for oxygen in India.

That contrast increased pressure on President Biden to act, and today his administration said it would support waiving intellectual property protections for Covid-19 vaccines to help produce more doses globally.

Previously, the U.S. had been a major holdout over a proposal at the World Trade Organization to suspend intellectual property protections. But this afternoon, Katherine Tai, the U.S. trade representative, announced the administration's support.

Ms. Tai said that the U.S. would participate in negotiations over the matter at the W.T.O., adding that they would take time. Further discussions are expected in the coming weeks, as India and South Africa, which proposed the waiver, are preparing a revised plan.

Activists have also said that the waiver must be accompanied by the process known as "tech transfer," in which patent holders supply technical know-how and personnel. "This is a start," said Gregg Gonsalves, a Yale University epidemiologist who has been pressing for the waiver. "We need the writing of the text of this waiver now to be transparent and public, but as we have always said, we need tech transfer now."

Vaccine rollout

  • Canada authorized the Pfizer vaccine to be used in people as young as 12. Its regulatory agency said it lowered the minimum age from 16 after a review of data from clinical trials in the U.S.
  • The governor of New York outlined new seating rules for vaccinated baseball fans, and said Broadway would start to reopen on Sept. 14.
  • Moderna said a "tweaked" version of its vaccine successfully neutralized concerning variants in lab trials, the Guardian reports.
  • A social science experiment suggests $100 vaccination incentives can pay off.
SUBSCRIBE TODAY

If you've found this newsletter helpful, please consider subscribing to The New York Times — with this special offer. Your support makes our work possible.

What else we're following

What you're doing

I came out as trans to my parents over the pandemic. It's been like pulling teeth to get medical attention. I have been on several waiting lists to have my first trans health appointment for almost a year. I lost my primary care physician back in October. I know I'm not the only one struggling to have my non-Covid health care needs met. It's difficult for everyone right now. But I feel frustrated. Like becoming myself has been put on hold.

— Lief Laible, Philadelphia

Let us know how you're dealing with the pandemic. Send us a response here, and we may feature it in an upcoming newsletter.

Email your thoughts to briefing@nytimes.com. Did a friend forward you the briefing? Sign up here.

Need help? Review our newsletter help page or contact us for assistance.

You received this email because you signed up for Coronavirus Briefing from The New York Times.

To stop receiving these emails, unsubscribe or manage your email preferences.

Subscribe to The Times

Connect with us on:

facebooktwitterinstagram

Change Your EmailPrivacy PolicyContact UsCalifornia Notices

The New York Times Company. 620 Eighth Avenue New York, NY 10018

No comments:

Post a Comment